Insider Buy/Sell Details for the Biotechnology Industry — Last 3 Months
Ratio0.2:1
Daily Buy & Sell Volume
Transactions (3032)
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
160
Price
$552.86
Total Value
$88.46K
Shares Held After
325,763
% of Holdings
0.0%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
725
Price
$551.82
Total Value
$400.07K
Shares Held After
325,923
% of Holdings
0.2%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
432
Price
$550.99
Total Value
$238.03K
Shares Held After
326,648
% of Holdings
0.1%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
757
Price
$549.59
Total Value
$416.04K
Shares Held After
327,080
% of Holdings
0.2%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
1,206
Price
$548.87
Total Value
$661.94K
Shares Held After
327,837
% of Holdings
0.4%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
1,171
Price
$547.99
Total Value
$641.70K
Shares Held After
329,043
% of Holdings
0.4%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
309
Price
$546.75
Total Value
$168.94K
Shares Held After
330,214
% of Holdings
0.1%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
1,280
Price
$544.90
Total Value
$697.47K
Shares Held After
330,523
% of Holdings
0.4%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
1,032
Price
$544.17
Total Value
$561.59K
Shares Held After
331,803
% of Holdings
0.3%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
408
Price
$542.87
Total Value
$221.49K
Shares Held After
332,835
% of Holdings
0.1%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
700
Price
$542.06
Total Value
$379.44K
Shares Held After
333,243
% of Holdings
0.2%
Alkermes plc. (ALKS)
Gaffin David Joseph — EVP, CLO, Alkermes, Inc.
Shares
2,034
Price
$41.03
Total Value
$83.46K
Shares Held After
221,388
% of Holdings
0.9%
Stoke Therapeutics, Inc. (STOK)
Allan Jonathan — GENERAL COUNSEL&CORP SEC
Shares
627
Price
$26.33
Total Value
$16.51K
Shares Held After
20,598
% of Holdings
3.0%
Nurix Therapeutics, Inc. (NRIX)
Ring Christine — Chief Legal Officer
Shares
5,786
Price
$23.19
Total Value
$134.15K
Shares Held After
9,110
% of Holdings
38.8%
BioNTech SE (BNTX)
Sahin Ugur — Chief Executive Officer
Shares
17,000
Price
$96.72
Total Value
$1.64M
Shares Held After
180,209
% of Holdings
8.6%
Greenland Mines Ltd (GRML)
El-Dada Riad Hussein — Former Director
Shares
3,500
Price
$9.35
Total Value
$32.73K
Shares Held After
0
% of Holdings
100.0%
Adaptive Biotechnologies Corp (ADPT)
RUBINSTEIN JULIE — President and COO
Shares
5,800
Price
$28.56
Total Value
$165.65K
Shares Held After
377,802
% of Holdings
1.5%
Adaptive Biotechnologies Corp (ADPT)
RUBINSTEIN JULIE — President and COO
Shares
6,081
Price
$27.57
Total Value
$167.65K
Shares Held After
383,602
% of Holdings
1.6%
Adaptive Biotechnologies Corp (ADPT)
LO FRANCIS — Chief People Officer
Shares
18,698
Price
$28.61
Total Value
$534.95K
Shares Held After
220,867
% of Holdings
7.8%
Adaptive Biotechnologies Corp (ADPT)
LO FRANCIS — Chief People Officer
Shares
8,094
Price
$27.52
Total Value
$222.75K
Shares Held After
239,565
% of Holdings
3.3%
CORCEPT THERAPEUTICS INC (CORT)
Maduck Sean — President, Corcept Endocrinology
The power of attorney under which this form was signed is on file with the Commission.
Shares
413
Price
$115.54
Total Value
$47.72K
Shares Held After
9,938
% of Holdings
4.0%
CORCEPT THERAPEUTICS INC (CORT)
Lyon Joseph Douglas — Chief Accounting&Technology Officer
Shares
810
Price
$115.40
Total Value
$93.47K
Shares Held After
5,683
% of Holdings
12.5%
BELITE BIO, INC (BLTE)
Scholl Hendrik Peter — Chief Medical Officer
Shares
2
Price
$170.02
Total Value
$340.04
Shares Held After
14,500
% of Holdings
0.0%
BELITE BIO, INC (BLTE)
Scholl Hendrik Peter — Chief Medical Officer
Shares
14
Price
$169.36
Total Value
$2.37K
Shares Held After
14,502
% of Holdings
0.1%
BELITE BIO, INC (BLTE)
Scholl Hendrik Peter — Chief Medical Officer
Shares
12
Price
$168.21
Total Value
$2.02K
Shares Held After
14,516
% of Holdings
0.1%
BELITE BIO, INC (BLTE)
Scholl Hendrik Peter — Chief Medical Officer
Shares
78
Price
$167.59
Total Value
$13.07K
Shares Held After
14,528
% of Holdings
0.5%
BELITE BIO, INC (BLTE)
Scholl Hendrik Peter — Chief Medical Officer
Shares
50
Price
$166.44
Total Value
$8.32K
Shares Held After
14,606
% of Holdings
0.3%
BELITE BIO, INC (BLTE)
Scholl Hendrik Peter — Chief Medical Officer
Shares
120
Price
$165.49
Total Value
$19.86K
Shares Held After
14,656
% of Holdings
0.8%
BELITE BIO, INC (BLTE)
Scholl Hendrik Peter — Chief Medical Officer
Shares
24
Price
$164.64
Total Value
$3.95K
Shares Held After
14,776
% of Holdings
0.2%
BELITE BIO, INC (BLTE)
Scholl Hendrik Peter — Chief Medical Officer
Shares
200
Price
$163.62
Total Value
$32.73K
Shares Held After
14,800
% of Holdings
1.3%
Grace Therapeutics, Inc. (GRCE)
Opaleye Management Inc. — 10% Owner
Shares
38,796
Price
$2.04
Total Value
$78.96K
Shares Held After
2,836,963
% of Holdings
1.4%
X4 Pharmaceuticals, Inc (XFOR)
KIRSKE DAVID — Chief Financial Officer
Shares
11,767
Price
$2.86
Total Value
$33.66K
Shares Held After
155,983
% of Holdings
7.0%
Roivant Sciences Ltd. (ROIV)
Epperly Melissa B, — Director
Shares
900
Price
$36.57
Total Value
$32.91K
Shares Held After
14,954
% of Holdings
5.7%
Roivant Sciences Ltd. (ROIV)
Epperly Melissa B, — Director
Shares
16,850
Price
$36.08
Total Value
$607.95K
Shares Held After
15,854
% of Holdings
51.5%
Monopar Therapeutics (MNPR)
STARR CHRISTOPHER M — Director
Shares
799
Price
$79.67
Total Value
$63.66K
Shares Held After
5,173
% of Holdings
13.4%
Monopar Therapeutics (MNPR)
STARR CHRISTOPHER M — Director
Shares
2,970
Price
$78.82
Total Value
$234.10K
Shares Held After
5,972
% of Holdings
33.2%
Monopar Therapeutics (MNPR)
STARR CHRISTOPHER M — Director
Shares
4,631
Price
$78.09
Total Value
$361.63K
Shares Held After
8,942
% of Holdings
34.1%
InMed Pharmaceuticals Inc. (INM)
ADAR1 Capital Management, LLC — 10% Owner
Shares
16,431
Price
$1.33
Total Value
$21.85K
Shares Held After
908,532
% of Holdings
1.8%
PALISADE BIO, INC. (PALI)
Williams Donald Allen — Director
Shares
10,000
Price
$1.42
Total Value
$14.20K
Shares Held After
1,580,294
% of Holdings
0.6%
Enliven Therapeutics, Inc. (ELVN)
Garland J. Scott — Director
Shares
13,000
Price
$46.67
Total Value
$606.72K
Shares Held After
0
% of Holdings
100.0%
Jazz Pharmaceuticals plc (JAZZ)
COZADD BRUCE C — Director
Shares
6,000
Price
$230.33
Total Value
$1.38M
Shares Held After
345,875
% of Holdings
1.7%
Spyre Therapeutics, Inc. (SYRE)
King-Jones Heidy — Chief Legal Officer and Corporate Secretary
Shares
2,600
Price
$93.46
Total Value
$243.00K
Shares Held After
2,845
% of Holdings
47.8%
Spyre Therapeutics, Inc. (SYRE)
King-Jones Heidy — Chief Legal Officer and Corporate Secretary
Shares
2,100
Price
$92.70
Total Value
$194.67K
Shares Held After
5,445
% of Holdings
27.8%
Spyre Therapeutics, Inc. (SYRE)
King-Jones Heidy — Chief Legal Officer and Corporate Secretary
Shares
7,228
Price
$91.35
Total Value
$660.28K
Shares Held After
7,545
% of Holdings
48.9%
Spyre Therapeutics, Inc. (SYRE)
King-Jones Heidy — Chief Legal Officer and Corporate Secretary
Shares
16,605
Price
$90.35
Total Value
$1.50M
Shares Held After
14,773
% of Holdings
52.9%
Spyre Therapeutics, Inc. (SYRE)
King-Jones Heidy — Chief Legal Officer and Corporate Secretary
Shares
400
Price
$89.24
Total Value
$35.70K
Shares Held After
31,378
% of Holdings
1.3%
Spyre Therapeutics, Inc. (SYRE)
Burrows Scott L — Chief Financial Officer
Shares
229
Price
$93.57
Total Value
$21.43K
Shares Held After
79,762
% of Holdings
0.3%
Spyre Therapeutics, Inc. (SYRE)
Burrows Scott L — Chief Financial Officer
Shares
3,071
Price
$92.95
Total Value
$285.45K
Shares Held After
79,991
% of Holdings
3.7%
Spyre Therapeutics, Inc. (SYRE)
Burrows Scott L — Chief Financial Officer
Shares
2,100
Price
$91.92
Total Value
$193.03K
Shares Held After
83,062
% of Holdings
2.5%
Spyre Therapeutics, Inc. (SYRE)
Burrows Scott L — Chief Financial Officer
Shares
1,500
Price
$90.27
Total Value
$135.41K
Shares Held After
85,162
% of Holdings
1.7%
3032 transactions